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Abstract
Toll-like receptors (TLRs) play an important role in innate immune responses against pathogenic 
microorganisms or tissue damage. Nucleic acid (NA)-sensing TLRs localize in intracellular 
vesicular compartments and recognize foreign- and host-derived nucleotides. Inappropriate 
activation of NA-sensing TLRs can cause pathogenic inflammation and autoimmunity. Multiple 
regulatory mechanisms exist to limit recognition of self-NAs. This review summarizes recent 
progress that has been made in understanding how NA-sensing TLRs are regulated via trafficking, 
proteolytic cleavage, as well as ligand processing and recognition.
Introduction
The innate immune system recognizes microbes using a limited set of germline-encoded 
pattern recognition receptors (PRRs). These receptors have been evolutionarily selected to 
recognize highly conserved features of microbes, known as pathogen-associated molecular 
patterns (PAMPs) [1]. TLRs have emerged over the past 20 years as crucial PRRs. These 
receptors share common structural features: an extracellular leucine-rich-repeat (LRR) 
domain that binds to ligand, a transmembrane domain, and a cytosolic Toll/IL-1 receptor 
(TIR) homology domain. Activation of TLRs induces production of inflammatory cytokines 
and type I interferons as well as induction of adaptive immunity [2].
Nearly half of TLRs recognize nucleic acid ligands. TLR3, TLR7/8 and TLR9 reside 
intracellularly and respond to double-stranded RNA (dsRNA), single-stranded RNA 
(ssRNA) and DNA, respectively. TLR13 has been recently reported to recognize bacterial 
ribosomal RNA [3]. Although sensing of microbial nucleic acid is crucial for effective 
immunity, it raises the potential risk of self-recognition, which can lead to autoimmune 
disorders such as systemic lupus erythematosus (SLE) [4]. Multiple regulatory mechanisms 
have been developed by the host to prevent the activation of TLRs by self-derived nucleic 
acid. The first of these mechanisms is receptor localization. Localization within endosomal 
compartments limits the recognition of self-derived ligands that are released by dying cells 
and primarily found in the extracellular space [5]. This compartmentalization is reinforced 
by the requirement for proteolytic processing of NA-sensing TLRs. In order to become a 
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functional receptor, the extracellular LRR domain of TLR3, 7, 8, and 9 needs to be cleaved 
by endosome-resident proteases [6,7]. In this way, proteolysis of TLRs is inherently linked 
to their intracellular localization. In addition to strategies based on receptor 
compartmentalization, expression levels of TLRs have to be tightly controlled to avoid 
excessive stimulation. TLR7 is the prime example of this principle, as simply increasing 
TLR7 gene copy number can lead to autoimmune disease [8,9]. A suboptimal codon-bias of 
the Tlr7 gene has recently been shown to safeguard from excessive receptor expression by 
negatively impacting Tlr7 transcription and translation [10]. Besides regulation at the 
receptor level, there is emerging evidence that delivery and processing of nucleic acid 
ligands can influence TLR activation [11]. In this review we will highlight recent work on 
regulatory mechanisms targeting the trafficking of NA-sensing TLRs, receptor proteolysis, 
as well as recognition and processing of ligands.
Regulation of receptor trafficking
NA-sensing TLRs are known to traffic via the conventional secretory pathway (from ER to 
Golgi). Multiple levels of regulation underlie the trafficking of TLRs, including the initial 
steps of ER export. Several folding chaperones, including gp96 and PRAT4A, are involved 
in TLR protein folding within the ER [12–14]. Sorting of intracellular TLRs is controlled by 
the trafficking chaperone Unc93b1, which physically interacts with TLRs and regulates ER 
export and partitioning to endolysosomes [15,16]. A non-functional allele of Unc93b1 that 
abolishes this interaction (H412R) is retained in the ER and results in loss of endosomal 
TLR signaling in humans and mice [17,18]. Recently, another ER membrane protein, named 
LRRC59, has been shown to be involved in this process, likely by assisting the loading of 
NA-sensing TLRs into COPII vesicles [19]. In spite of these findings, how Unc93b1 or 
LRRC59 coordinate with other factors for exporting TLRs from the ER remains poorly 
understood.
All nucleic acid sensing TLRs traffic to endosomes via an Unc93b1-dependent manner and 
studies of Unc93b1 reveal potential competition between individual TLRs during trafficking. 
For instance, the Unc93b1 D34A mutation results in preferred interaction and trafficking of 
TLR7 over TLR9 and leads to TLR7-dependent lethal inflammation in mice [20,21]. The 
competition between TLR7 and -9 might explain the opposing roles of these two receptors in 
lupus mouse models, where disease is ameliorated by the loss of TLR7 but paradoxically 
exacerbated by the loss of TLR9 [22,23]. These results indicate a role of Unc93b1 in 
preventing aberrant NA-sensing TLR responses via controlling their ER export rates 
distinctly. Whether the selective trafficking of TLRs by Unc93b1 relies on additional 
proteins remains an unsolved question.
NA-sensing TLRs are believed to function in multiple intracellular organelles. Several 
mechanisms that regulate sorting of TLRs to specialized signaling compartments have been 
described. For example, TLR9 is sorted to lysosomal compartments through multi-vesicular 
bodies by ESCRT system. The compartmentalization of TLR9 in this process requires its 
ubiquitination [24]. Another example of specialized trafficking of TLRs between 
intracellular organelle subtypes depends on Adaptor Protein 3 (AP-3). In macrophages, 
AP-3 is responsible for the trafficking of TLR9 from endosomes to a specialized lysosome-
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related organelle, where activation of TLR9 leads to production of type I IFN rather than 
proinflammatory cytokines [25]. This concept of specialized signaling endosomes was first 
appreciated by comparing the TLR9 response to oligonucleotides with differential access to 
these specialized endosomes [26]. Since the initial introduction of this concept not much 
progress has been made toward understanding the cell biology underlying these 
observations. One reason might be the challenge in identifying subpopulations of endosomes 
and lysosomes involved in TLR signaling, due to the highly dynamic nature of the endocytic 
membrane system and lack of sufficient endosomal markers. Moreover, cell type-specific 
variations of the endosomal landscape and differences in TLR trafficking further complicate 
the picture. At this point we do not have a generalized view of the logic underlying 
specialized TLR signaling compartments.
As critical innate immune sensors, NA-sensing TLRs are continually trafficked to 
endosomal compartments even in the absence of infection. However, TLR trafficking can be 
regulated at different levels in response to nucleic acid ligands. There is evidence that the ER 
export rate of TLR9 is modulated as a result of CpG oligonucleotide stimulation [27,28]. 
Phosphorylation of TLR9 by Src kinases is necessary for its appropriate intracellular 
localization and stability [29,30]. Another example from TLR3 studies indicates that TLR 
trafficking from early endosomes into late endosomes can also be modulated in response to 
synthetic ligands or pathogens [31]. Notably, all this regulation seem to function in a TLR-
specific manner, which may help the host control response levels against specific stimuli 
without disturbing overall immune homeostasis. Ligand-induced regulation provides the 
host a way to set up feedback mechanisms in response to nucleic acid ligands. The 
coordination between ligand-dependent and –independent regulation of NA-sensing TLR 
trafficking requires further investigation.
Proteolytic processing of TLRs
By restricting the functional form of TLRs to endosomal compartments, proteolytic 
processing has been appreciated as a crucial regulatory checkpoint to limit self-recognition. 
Additional levels of this regulation are cell type or receptor-specific differences among the 
cellular compartments in which the processing takes place, the enzymes involved in TLR 
cleavage and their pH requirements; all of which allow a fine-tuned regulation of receptor 
processing among different cell types or under different cellular activation states.
Lysosomal cathepsins and asparagine endopeptidases with acidic pH optima have been 
implicated in the cleavage of TLRs [6,32–34], with the exception of human TLR7 and -8. 
These two receptors can be cleaved by the furin-like proprotein convertase, which operates 
at neutral pH and might therefore generate functional hTLR7 and -8 before they reach acidic 
endosomes [7,35]. Cleavage of TLR9 seems to be a pre-requisite for TLR activation, as a 
pre-cleaved receptor (lacking the N-terminal half of the ectodomain) does not support TLR9 
activation [36,37]. Puzzling at first, this observation can now be explained by the fact that 
the N-terminal cleavage product has to stay associated with the C-terminal half to form a 
functional receptor [36]. This principle also applies to the other NA-sensing TLRs [7,38,39]. 
Consistent with this finding, the crystal structures of TLR7, -8, and -9 provide structural 
evidence for the requirement of TLR processing and the continuing association of the two 
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cleavage products [40–42]. As a unifying rule, nucleic acid ligands for TLR3, -7, -8 and -9 
seem to directly contact both the N-terminal and C-terminal half of the receptor, forming a 
“molecular bridge” holding the individual pieces together [40–43]. In the case of TLR7, an 
additional disulfide bond between Cys98 and Cys475 links the N-terminal fragment to the 
rest of the receptor [38], whereas no covalent interactions have been detected for the other 
TLRs.
The fact that the N-terminal fragment remains associated with endosomal TLRs after 
proteolytic cleavage raises the question of what role proteolytic processing plays. 
Biochemical as well as structural studies of TLR8 and -9 reveal that proteolytic cleavage is 
dispensable for ligand binding, as uncleaved receptor binds equally well to nucleic acid 
ligands [40,44,45]. Instead, processing is required for ligand-induced oligomerization of the 
two TLR protomers, as without processing the uncleaved Z-loop region has been suggested 
to sterically interfere with receptor dimerization [45].
In summary, the proteolytic cleavage of intracellular TLRs neither releases the N-terminal 
half nor alters the overall receptor conformation. However, it profoundly impacts ligand-
mediated dimerization and activation of TLRs.
TLR structure and ligand recognition
TLRs have been notoriously difficult to crystallize. Only recently, the structure of TLR7 
bound to its natural ligands has been solved, so that finally structures are available for TLR3, 
-7, -8, and -9 [40,42,43,46].
There is still inconsistency of whether NA-sensing TLRs exist as a monomer or dimer 
before ligand engagement. The unbound ectodomain (ECD) of TLR3 has been shown to 
crystallize as a monomer [47], as does the ectodomain of TLR9. Upon addition of ligand 
both TLR3 and -9 form dimers. However, another study looking at full-length TLR9 in cells 
suggested that TLR9 exists as a pre-formed homodimer and ligand binding simply induces a 
conformational change necessary for receptor activation [48]. The discrepancy between 
these findings may be explained by the incomplete structural information, which only 
considers the TLR ECDs and therefore, might not reflect the physiological condition of full-
length receptor within a cell.
The structure of TLR9 reveals that binding of agonist DNA contacts the N-terminal 
fragment of one TLR9 and the C-terminal half of another TLR9 molecule, inducing ligand-
dependent dimerization [40]. In contrast, inhibitory DNA only interacts with the N-terminal 
fragment and does not trigger dimerization of TLR9. It has been well appreciated that the 
immunostimulatory activity of oligonucleotides is sequence-dependent and requires a core 
CpG motif [49]. The differential interaction of agonist and inhibitory DNA with the TLR9 
ECD provides the first mechanistic explanation for this sequence-dependent regulation. 
Furthermore, methylated CpG yield weaker binding to and dimerization of TLR9 compared 
to ummethylated CpG, supporting the original paradigm that TLR9 evolved to sense 
bacterial-derived unmethylated DNA. As all of these studies have been using synthetic short 
CpG-oligonucleotides, the question still remains how TLR9 deals with the recognition of 
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complex genomic DNA. Assuming that genomic DNA is degraded within the endolysosome 
into random fragments with varying immunogenicity, the ability to overcome the activation 
threshold of TLR9 may be a function of competition between agonist and inhibitory DNA 
sequences and may depend on the species-specific genomic GC content or the epigenetic 
status of the DNA.
TLR7 and 8 seem to recognize their ligands in a manner distinct from ligand binding by 
TLR9. The TLR7 structure reveals two ligand-binding sites that function synergistically in 
the activation of the receptor [42]. The first site is occupied by a single guanosine (or its 
derivatives), which is sufficient to induce receptor dimerization. The second site binds a 
short ssRNA oligoribonucleotide preferable containing a non-terminal uridine. Binding of 
the second ligand synergistically enhances the affinity for guanosine to the first site. An 
analogous mechanism of ligand recognition is employed by TLR8, although uridine is 
preferred over guanosine in the first binding site [46,50].
None of the two ligands alone is sufficient to induce TLR7 activation. Thus, TLR7 is a dual 
receptor for guanosine and uridine-containing ssRNA. Similar to the sequence-dependency 
of TLR9 ligands, the ssRNA sequence determines the binding affinity and activation of 
TLR7. Interestingly, the synthetic guanosine analog R848 (Resiquimod) binds in a similar 
manner to TLR7 as guanosine. However, slightly different amino acid contacts compared to 
guanosine and a higher overall affinity makes this small-chemical ligand sufficient to 
activate TLR7 even in the absence of ssRNA.
Cargo handling and processing of ligands
TLR ligands themselves are subject to regulation. The stimulatory capacity of ligands 
depends on the type of ligand, local concentration, stability, the mode of uptake, as well as 
the type of endosomes these ligands can access. Generally, nucleic acids alone are not 
sufficient to break TLR tolerance, but association with molecules that protect them from 
degradation can transform them into potent TLR activators. A number of accessory proteins 
have been discovered that bind to DNA or RNA and facilitate their uptake and activation of 
TLRs. Also nucleic acids presented in the form of immune complexes are very potent 
activators of TLRs. During conditions of autoinflammation or autoimmunity, accessory 
proteins and immune complexes are found in higher serum concentrations and contribute to 
enhanced self-recognition and inflammation. We refer readers interested in this particular 
subject to several excellent reviews [44,51].
A major mechanism to prevent self-recognition through TLR9 is the continuous degradation 
of DNA by DNases. Recently, DNases have also been shown to be required for TLR9 
activation by processing DNA into shorter stimulatory cleavage products [52]. These 
findings place DNases as critical regulators of TLR9 activation by controlling the 
availability of stimulatory ligands in vivo. Three different DNase families exist: DNase I, II, 
and III, which are localized and operate in the circulation, lysosomes, or the cytoplasm, 
respectively. Lack or loss-of-function of DNase I causes lupus-like disease in humans and 
mice [53,54]. The specific receptors responsible for recognition of the undigested DNA 
remain to be identified. Likewise, deficiency of DNase I-like III, another member of the 
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DNase I family, causes an aggressive form of familial SLE [55]. In contrast to DNase I, 
DNase I-like III has the ability to degrade DNA encapsulated in lipids or in the form of 
dense chromatin particles [56,57]. Accordingly, DNase I-like III-deficient mice experience 
an elevated concentration of circulating DNA-containing microparticles and develop 
autoantibodies to DNA and chromatin, followed by an SLE-like disease [58]. The clinical 
manifestations could be completely rescued by MyD88 deficiency, indicating a role for 
TLRs in sensing the DNA-containing microparticles. DNase II deficiency causes 
accumulation of DNA in lysosomes and lethal anemia in mice [59]. Surprisingly, TLR9 has 
been ruled out as the sensor for lysosomal DNA in this model. Instead, accumulated DNA 
seems to leak out into the cytosol and induces Sting and Aim2-mediated inflammation, two 
cytosolic DNA sensing pathways [60,61]. The inability of TLR9 to respond to accumulated 
DNA in lysosomes could be later explained by the requirement of DNase II to process and 
provide suitable DNA pieces for TLR9 activation [52]. This idea is also in line with 
structural data showing that TLR9 does not bind to dsDNA, emphasizing the need for 
processing to generate ssDNA [40].
Likewise, TLR7 and –8 are stimulated by breakdown products of RNA, such as guanosine or 
uridine, and TLR3 binds dsRNA fragments of 40–50 nucleotides of length. Analogous to the 
function of DNase II, this would predict the existence of processing mechanisms for 
endosomal RNA sensors. So far, the specific enzymes (RNases and phosphatases) involved 
in processing of lysosomal RNA have not been identified.
In addition to guanosine, TLR7 can also bind and respond to deoxyguanosine, a breakdown 
product of DNA [62]. This raises the possibility that, in addition to RNA, TLR7 can also 
respond to DNA degradation products in the presence of oligoribonucleotides. This theory 
might shed light on the puzzling observation that DNase II-deficient mice show elevated 
anti-RNA antibodies, suggesting that accumulated DNA in lysosomes can activate TLR7 
[63].
Altogether, these examples raise interesting possibilities about the initial source of nucleic 
acid breakdown products for TLR7. Nucleosides could be derived from the cytosol of dying 
cells as intermediates of nucleic-acid metabolism, whereas nucleotides could simply be 
breakdown products of digested DNA and RNA. Future studies will hopefully elucidate how 
nucleic acids are being degraded in the lysosome, identify the required enzymes, and 
decipher how nucleic-acid metabolism may regulate innate immune sensing.
Concluding remarks
Considering the multitude of TLRs that have evolved to sense nucleic acids, the recognition 
of microbial DNA or RNA clearly represents a key strategy by which the innate immune 
system detects infection. However, the detection of nucleic acids comes with the risk of self-
recognition and autoimmunity. Therefore, tight regulation of NA-sensing TLRs at multiple 
levels is required to limit responses against self. For some of these regulatory principles the 
field has made considerable progress within the last years, including the critical role of 
Unc93b1 in TLR trafficking and signaling, structural evidence for receptor proteolysis and 
ligand recognition, as well as the processing of nucleic acids. Yet, there are still many open 
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questions about the endogenous source and the nature of these nucleic acid ligands, the 
diverse pathways regulating TLR trafficking to endosomes, and the components that define 
endosomes with distinct TLR signaling properties. Better knowledge of the regulatory 
mechanisms of intracellular TLR signaling will shed light on the pathogenesis of 
autoimmunity and inflammatory diseases and will provide important clues for the 
development of new diagnostics and therapeutic approaches to treat these diseases.
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• Nucleic acid-sensing TLRs are regulated at multiple levels to maintain 
immunological tolerance to host-derived ligands.
• The recently solved crystal structures of TLR7, -8, and -9 provide evidence 
for the need of proteolytic processing and the mode of ligand binding.
• TLR7 and -8 are dual receptors for single nucleosides and short ssRNA 
oligoribonucleotides
• The need for ligand processing to generate stimulatory nucleic acid fragments 
emerges as a new principle for TLR activation
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Self versus non-self discrimination by NA-sensing TLRs and how dysregulated responses 
can lead to autoimmunity. The intracellular localization of NA-TLRs limits the recognition 
of self-nucleic acids that are derived from dying cells and primarily found in the 
extracellular space. DNases continuously degrade free DNA to avoid autoimmune responses. 
Upon infection, microbial DNA is released into the endolysosome, where it engages with 
TLRs and triggers a protective immune response. 1) Accumulation of self-nucleic acids due 
to defective clearance, 2) elevated levels of stabilizing proteins that protect DNA/RNA from 
degradation, 3) deficient degradation of nucleic acids, 4) as well as increased TLR7 levels 
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can lead to autoimmunity. In some instances, infections can also trigger or exacerbate 
autoimmunity.
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Trafficking pathways regulating the localization of NA-sensing TLRs. Unc93b1 interacts 
with all NA-sensing TLRs in the ER and facilitates export into COPII vesicles. Unc93b1 
remains associated with TLRs after exit from the ER. Individual TLRs may access distinct 
intracellular compartments and are subject to specific sorting mechanisms. AEP: asparagine 
endopeptidase; ESCRT: endosomal sorting complexes required for transport; LRO: 
lysosome-related organelle; PC: proprotein convertase.
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Nucleic acid processing and ligand binding by TLRs. Foreign as well as self-derived nucleic 
acids are delivered to the endolysosome where they are further processed by either DNase II 
or an unknown RNase to yield shorter fragments that can activate TLRs. TLR9 binds to 
short single-stranded oligonucleotides with a stimulatory core CpG motif. TLR7/8 recognize 
nucleoside breakdown products as well as oligoribonucleotides. TLR3 is activated by 
dsRNA.
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